Pharmaceuticals, Biotechnology and Life Sciences
INEOS Styrolution, the global player in styrenics, has announced two new styrenics grades, both of which designed for very specific use by medical device manufacturers.
Pharmapack 2017, kicking off on February 1, 2017 marks 20 years of Pharmapack. We talked with Anne Schumacher, Brand Director at Pharmapack Europe.
Sanofi announced on Wednesday two approvals for its drugs in North America. Rheumatoid arthritis drug, which it has made in cooperation with Regeneron Pharmaceuticals, has been approved by Health Canada and the U.S. Food and Drug Administration (FDA) has approved Xyzal Allergy 24HR
Several leaders of some of the largest pharmaceutical companies have met on Tuesday with the newly elected US president, Donald Trump to discuss industry related topics, agreeing that the talks were positive.
The newly appointed president of the United States of America, Donald Trump said that he wants pharmaceutical companies to manufacture their products in America, during the meeting he held with leaders of some of the major drugmakers.
U.S. President Donald Trump, who has accused drugmakers of “getting away with murder” on prices, will meet executives from the pharmaceutical industry at the White House on Tuesday.
Driven by new products, including Trulicity, Cyramza, Jardiance and Taltz, Lilly’s volume-driven significant growth in 2016.
Onxeo, an oncology French-based focused drugmaker and a cancer researcher, the Institut Curie, have kicked off several cancer studies, to test the combination of radiotherapy, DNA repair inhibitors and immunotherapy.
GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.
India’s health ministry is likely to see a substantial increase in funding, after it warned that its programs were short of cash and sought more than $1.2 billion in additional money